Tessa Romero
Stock Analyst at JP Morgan
(3.83)
# 650
Out of 4,918 analysts
65
Total ratings
44.9%
Success rate
12.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Overweight | $30 → $34 | $23.53 | +44.50% | 9 | Jul 24, 2025 | |
| DYN Dyne Therapeutics | Maintains: Neutral | $10 → $9 | $10.05 | -10.45% | 6 | Jul 15, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $68 → $55 | $14.71 | +273.90% | 7 | Jun 18, 2025 | |
| CYTK Cytokinetics | Maintains: Overweight | $71 → $53 | $36.69 | +44.45% | 5 | Jun 9, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Overweight | $16 → $10 | $4.61 | +116.92% | 2 | May 30, 2025 | |
| UPB Upstream Bio | Initiates: Overweight | $38 | $15.51 | +145.00% | 1 | Nov 5, 2024 | |
| NMRA Neumora Therapeutics | Downgrades: Neutral | $18 → $15 | $1.56 | +861.54% | 4 | Nov 5, 2024 | |
| MCRB Seres Therapeutics | Downgrades: Underweight | n/a | $13.70 | - | 2 | Oct 24, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $18 → $31 | $36.46 | -14.98% | 5 | Oct 14, 2024 | |
| EYPT EyePoint Pharmaceuticals | Maintains: Overweight | $32 → $29 | $9.73 | +198.05% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $31 | $14.36 | +115.88% | 8 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $46 | $35.05 | +31.24% | 6 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $4.53 | +54.53% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $55 | $30.48 | +80.45% | 2 | Apr 25, 2023 |
ACADIA Pharmaceuticals
Jul 24, 2025
Maintains: Overweight
Price Target: $30 → $34
Current: $23.53
Upside: +44.50%
Dyne Therapeutics
Jul 15, 2025
Maintains: Neutral
Price Target: $10 → $9
Current: $10.05
Upside: -10.45%
Biohaven
Jun 18, 2025
Maintains: Overweight
Price Target: $68 → $55
Current: $14.71
Upside: +273.90%
Cytokinetics
Jun 9, 2025
Maintains: Overweight
Price Target: $71 → $53
Current: $36.69
Upside: +44.45%
Lexeo Therapeutics
May 30, 2025
Maintains: Overweight
Price Target: $16 → $10
Current: $4.61
Upside: +116.92%
Upstream Bio
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $15.51
Upside: +145.00%
Neumora Therapeutics
Nov 5, 2024
Downgrades: Neutral
Price Target: $18 → $15
Current: $1.56
Upside: +861.54%
Seres Therapeutics
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $13.70
Upside: -
Scholar Rock Holding
Oct 14, 2024
Maintains: Overweight
Price Target: $18 → $31
Current: $36.46
Upside: -14.98%
EyePoint Pharmaceuticals
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $9.73
Upside: +198.05%
Aug 12, 2024
Maintains: Overweight
Price Target: $30 → $31
Current: $14.36
Upside: +115.88%
Jun 13, 2024
Reinstates: Neutral
Price Target: $46
Current: $35.05
Upside: +31.24%
Aug 22, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $4.53
Upside: +54.53%
Apr 25, 2023
Maintains: Overweight
Price Target: $54 → $55
Current: $30.48
Upside: +80.45%